扶正和胃方联合瑞巴派特治疗脾胃虚弱证慢性浅表性胃炎的效果及安全性分析

Efficacy and Safety of Fuzheng Hewei Prescription Combined with Rebamipide for Chronic Superficial Gastritis in Patients Diagnosed with Weakness of the Spleen and Stomach

目的探讨扶正和胃方联合瑞巴派特治疗脾胃虚弱证慢性浅表性胃炎(CSG)的效果及对复发的影响,并分析其安全性。方法选择2021年4月至2023年1月收治的脾胃虚弱证CSG患者106例,按随机数字表法分为观察组与对照组各53例。对照组给予瑞巴派特片治疗,观察组在对照组基础上联合扶正和胃方治疗。对比2组临床疗效、症状改善时间、治疗前后中医证候积分及生活质量评分、胃功能指标[血清内皮素-1、表皮生长因子(EGF)、血清胃蛋白酶原Ⅰ(PGⅠ)、胃泌素-17]水平变化,观察2组不良反应及复发情况。结果观察组总有效率[96.23%(51/53)]高于对照组[83.02%(44/53)],差异有统计学意义(P<0.05)。观察组症状改善时间短于对照组(P<0.01)。观察组治疗后中医证候积分低于对照组、健康调查简表评分高于对照组(P<0.01)。观察组内皮素-1、EGF水平低于对照组,PGⅠ、胃泌素-17高于对照组(P<0.01)。2组不良反应发生率比较差异无统计学意义(P>0.05)。观察组复发率[1.89%(1/53)]低于对照组[13.21%(7/53)],差异有统计学意义(P<0.05)。结论扶正和胃方联合瑞巴派特治疗脾胃虚弱证CSG患者临床效果显著,可改善症状和胃肠功能,提高生活质量,降低复发率,且安全性较高。

Objective To investigate the therapeutic effect of Fuzheng Hewei prescription combined with Rebamipide in the treatment of chronic superficial gastritis(CSG)in patients with weakness of the spleen and stomach and its impact on recurrence,and to analyze its safety.Methods In total,106 CGS patients with weakness of the spleen and stomach treated from April 2021 to January 2023 were selected and divided into observation group(n=53)and control group(n=53)ac-cording to random number table method.The control group was treated with Rebamipide tablets,and the observation group was treated with Fuzheng Hewei prescription on the basis of control group.The clinical efficacy,time to symptom improvement,traditional Chinese medicine(TCM)syndrome score and quality of life score before and after treatment,and gastric function indexes[serum endothelin-1(ET-1),epidermal growth factor(EGF),pepsinogenⅠ(PG-Ⅰ),gastrin-17(G-17)]levels were compared between the two groups,and adverse reactions and recurrence were observed.Results The total effective rate of the observation group[96.23%(51/53)]was higher than that of the control group[83.02%(44/53)],and the differ-ence was significant(P<0.05).Time to symptom improvement was shorter in the observation group than in the control group(P<0.01).After treatment,the TCM syndrome score of the observation group was lower than that of the control group,and the Short-Form 36 Health Survey Questionnaire(SF-36)score was higher than that of control group(P<0.01).The levels of ET-1 and EGF in the observation group were lower than those in the control group,while the levels of PG-Ⅰand G-17 were higher than those in the control group(P<0.01).There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).The recurrence rate of the observation group[1.89%(1/53)]was lower than that of control group[13.21%(7/53)],and the difference was significant(P<0.05).Conclusion Fuzheng Hewei prescription combined with Rebamipide has significant clinical effect in the treatment of CSG patients with weakness of the spleen and stomach,which can improve symptoms and gastric function,improve quality of life,and reduce recurrence rate,with good safety.